Highlights  Eg5 is a potential target for drug development in cancer chemotherapy  The thiadiazole scaffold containing inhibitors target the Eg5 motor domain  (S)-ARRY-520 has advanced to clinical phase III trials against multiple myeloma  The Eg5-K858 complex provides crucial insights into this important chemical scaffold  Using the crystal structure of the complex we rationalised our structure-activity relationship study
Introduction
Established tubulin-targeting chemotherapeutic drugs such as taxanes and vinca alkaloids are clinically proven anti-cancer agents. They target the mitotic spindle, a molecular machinery made of microtubules (MTs), which is responsible for chromosome segregation during cell division [1] [2] [3] . However, MTs are also key components in neuronal transport, and their disruption can lead to serious toxic side effects such as neurotoxicity [4] . Therefore, certain mitotic kinesins are investigated for their potential as novel drug targets with the hope to develop complementary treatment options and to reduce side effects.
The mitotic kinesin Eg5 (also called Kif11, Kinesin Spindle Protein, KSP), a member of the kinesin-5 subfamily [5] , is essential for establishing the bipolar mitotic spindle [6] . Structurally, Eg5 exists as a homotetramer via oligomerisation of the central stalk domain [7, 8] . As there is a second MT-binding site in the C-terminal tail domain, the quaternary structure of homotetrameric Eg5 imparts the functionality of crosslinking and sliding anti-parallel MTs apart, which is essential for centrosome separation during early stages of cell division [9] . Eg5 has become an attractive target for drug development in cancer chemotherapy since the discovery of monastrol, the first selective inhibitor of Eg5 [10] . The inhibition of Eg5 results in the formation of monopolar spindles, which leads to mitotic arrest and may lead to subsequent apoptotic cell death. As Eg5 is crucial and specific for mitosis, its inhibition would achieve anti-mitotic effects with fewer and less undesirable effects than have been observed for tubulin targeting agents [11] [12] [13] [14] .
Today, several inhibitors targeting Eg5 have entered phase I, II and III clinical trials either as monotherapies or in combination with other drugs [15] .
Clinical candidates targeting Eg5 show a variety of chemically distinct scaffolds, with thiadiazole-based (S)-ARRY-520 ( Figure 1 ) being the most encouraging inhibitor to enter phase III clinical trials as a combination therapy with a proteasome inhibitor for the treatment of multiple myeloma [16, 17] . Despite of the promising clinical results, it remains to be established where exactly (S)-ARRY-520 binds to the motor domain of Eg5 to exert its highly specific inhibitory effects. The structural information is urgently needed to understand why (S)-ARRY-520 is so successful in advancing into phase III clinical trials.
Another clinically relevant Eg5-targeting inhibitor containing the thiadiazole scaffold is (R)-Litronesib (also named LY2523355). (R)-Litronesib ( Figure 1 ) causes mitotic arrest and apoptotic cell death in tumour cells and has been shown to be active in a variety of mouse xenograft tumour models [18] . Dose finding and dose-escalating studies were conducted in a range of phase I clinical trials in advanced solid tumours [19, 20] in preparation for phase II trials. Later, it was shown that (R)-Litronesib displayed chiral instability leading to racemisation of the active enantiomer [21] .
Eventually, the drug candidate was discontinued for strategic reasons [22] . K858, the third example of an Eg5 inhibitor containing the thiadiazole as a core scaffold and which is structurally related to (S)-ARRY-520 and (R)-Litronesib ( Figure   1 ), was first discovered in a phenotype-based screen as a novel Eg5-specific inhibitor [23] . Racemic K858 (rK858) inhibited the MT-stimulated Eg5 ATPase activity (IC 50 = 1.3 µM) in an ATP-uncompetitive manner. It induced monoastral spindles, mitotic arrest and subsequent cells death in HTC116 tumour cells. It did not inhibit other human kinesins tested and did not influence MT dynamics in vitro nor had a detectable effect on the MT network in cells, indicating specificity for Eg5.
Even though it was not a very potent inhibitor against the MT-stimulated ATPase activity, it inhibited tumour growth in an A2780 ovarian cancer xenograft model and did not exhibit any neurotoxicity in this animal model. Importantly, it was also able to induce cell death in paclitaxel-resistant cancer cells, suggesting that rK858 may serve as a starting point for the development of more potent anti-cancer agents, based on the thiadiazole scaffold.
Recently, it has been shown that rK858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells [24] and also influences survivin-related chemoresistance in breast cancer cells [25] . While the anti-Eg5 and anti-tumour activities of rK858 have been characterised in cell-based assays and in vivo, the biochemical and structural basis for inhibiting Eg5 not only by rK858, but also for the other two thiadiazole containing derivatives (S)-ARRY-520 and (R)-Litronesib, are still unknown. Here, we further describe the inhibition effects of rK858 using biochemical and biophysical assays. We also determined two distinct crystal structures of the ternary complex of the human Eg5 motor domain in complex with Mg 2+ ADP and K858. Our crystal structures reveal important structural insights into how thiadiazole-containing compound binds to the allosteric drug-binding pocket of Eg5. This provides a first glimpse of the important thiadiazole scaffold as a potent inhibitor of Eg5 and has implications for further structure-based design. Finally, we conducted a structure-activity relationship (SAR) study by determining the IC 50 values for 46 analogues of K858 and rationally interpreted the results using the structure of the complex as a basis.
Results and Discussion
For biochemical experiments and co-crystallisation, rK858 was synthesised as previously described [26, 27] and its synthetic route is presented in Scheme 1 as a representative example for the thiadiazole derivatives (1-46) measured in this study. Acetophenone (a) in methanol was reacted with thiosemicarbazide (b) under vigorous stirring to afford (E)-2-(1-phenylethylidene)hydrazine-1-carbothioamide (c) quantitatively. The 1 H NMR data of c revealed that a singlet peak resonating at δ 10.27 ppm was attributed to the -NH proton. One of the thioamidic protons (-C=(S)NH 2 ) appeared as a singlet at δ 8.26 ppm, while the other proton had merged with the aromatic protons in the aromatic region between δ 7.91 -7.93 ppm.
Moreover, the methyl (CH 3 ) protons resonated at δ 2.29 ppm. In 13 C NMR, we observed a characteristic peak at δ 178.93 ppm which indicated the presence of the C=S functionality. The compound c undergoes a cyclisation and a subsequent acetylation reaction in acetic anhydride to give N-(4-acetyl-5-methyl-5-phenyl-4,5dihydro-1,3,4-thiadiazol-2-yl)acetamide (1) as a racemic mixture. The formation of 1 was confirmed by the presence of two additional methyl group protons appearing as distinctive singlets at δ 2.01 ppm and δ 2.19 ppm in the shielded region of 1 H NMR.
This has been further established in 13 C NMR where two new methyl group (CH 3 ) carbons appeared at δ 23.6 ppm and δ 26.5 ppm. In addition, two new carbonyl carbons (C=O) were also recorded at δ 167 and 169 ppm, respectively. Thus the structure of compound 1 (rK858), was confirmed based on 1 H and 13 C NMR spectral data, which corroborated with previous literature [23] . The syntheses and characterisation of the 46 selected K858 analogues investigated in our SAR study were recently described [28] .
Scheme 1:
Synthetic route for rK858 [26, 27] .
Biochemical and biophysical characterisation of inhibition of Eg5 by rK858
Although the inhibitory effect of rK858 on the MT-stimulated Eg5 ATPase activity has been reported [23] , we were curious whether rK858 was also able to directly bind to and inhibit the basal ATPase activity of Eg5. rK858 was capable of inhibiting the basal ATPase activity of Eg5 with an IC 50 value of 740 ± 0.4 nM ( Figure 2A ). To verify the inhibition of the MT-stimulated ATPase activity, the assays were repeated in the presence of MTs and we obtained an IC 50 value of 738 ± 0.3 nM, similar to the value obtained by Nakai and close to the IC 50 value for the inhibition of the basal ATPase activity ( Figure 2B ) [23, 29] . As a complementary assay, we also employed isothermal titration calorimetry (ITC) to determine the binding affinity of rK858 for Eg5. ITC analysis revealed that rK858 is a nanomolar inhibitor that tightly binds to 
Overall structure of the ADP-Eg5-K858 ternary complex
Since rK858 was capable to bind to and inhibit the basal ATPase activity of Eg5, this allowed us to set up crystallisation trials of the Eg5-K858 complex, in order to determine the structure of the ADP-Eg5-K858 ternary complex. We were able to crystallise the Eg5-rK858 complex in two distinct space groups and to determine the structures for both complexes, albeit at distinct resolutions (Table 1 ). In space group C222 1 , crystals diffracted to 1.8 Å resolution and contained one Eg5-rK858 complex per asymmetric unit (AU). In contrast, in the second condition, crystals formed in space group P6 5 22 with one molecule in the AU, but diffracted to only 2.8 Å resolution. In both crystal forms the complex structures represent the final inhibitor bound state. In this conformation, the switch II cluster is in the permissive position, allowing the neck-linker to dock to the motor domain ( Figure 3A and B). In the two molecules of the two distinct crystal forms, rK858 binds to the same pocket in an identical orientation. Due to the significantly higher resolution of the first crystal form, we will concentrate our subsequent structure interpretation using the high-resolution complex present in the C222 1 complex. are indicated as dotted lines. Leu214, which has been shown to be crucial for conferring resistance to K858 when mutated to alanine, is coloured in black.
Molecular insights into the K858 binding pocket
The magnification of the inhibitor binding pocket with bound K858 is shown in Figure   3D . K858 binds to the allosteric inhibitor-binding pocket formed by helix α2, loop L5 and helix α3. Although additional inhibitor binding pockets have previously been identified in Eg5 such as the α4/α6 pocket, an additional site in the MT binding region and a fourth site in or close to the nucleotide binding pocket, K858 binds to the well-established allosteric pocket, which accommodates several other Eg5 inhibitor scaffolds. Although we used the racemic mixture of K858 for crystallisation of the complex we exclusively observed electron density for the (R)-enantiomer in the loop L5 pocket, indicating enantio-selectivity for K858 ( Figure 3D ). Enantioselectivity has also been observed for ARRY-520 and Litronesib with the S and the R-enantiomers being the active compounds, respectively, although no structural data are available for these two thiadiazole containing clinical inhibitors yet. substituent. This trend is even more pronounced in the 5 th position, which displays a single methyl group in K858, whereas this small substituent is replaced by a 3aminopropyl group in (S)-ARRY-520 and a sulfonamido containing substituent in Litronesib. In the case of (S)-ARRY-520 we predict that the 3-aminopropyl group is destined to interact with Glu166 in Eg5, similar to the other inhibitors containing the aminopropyl group such as STLC, ispinesib and its second generation analogue SB-743921. Although the primary amine is known to be prone to hERG liabilities, this has not been reported in any of the clinical trials for (S)-ARRY-520.
Structure-based, rational interpretation of binding of a range of K858 analogues to the Eg5 inhibitor-binding pocket
Recently, some of us [28] synthesised about one hundred K858 analogues and tested their anti-proliferative potential against the human prostate cancer cell line (PC3) and two melanoma cell lines (SK-MEL-5 and SK-MEL-28). We were capable of identifying ten compounds with anti-proliferative activity and compared the results to the control compound rK858. These results were challenging to fully interpret in terms of the SAR, because drug-like properties of these compounds such as solubility, lipophilicity and cell permeability may have significant effects in cell-based assays as opposed to cell membrane-free biochemical assays. We therefore embarked on determining the IC 50 values of about 50 selected rK858 analogues all carrying modifications in the 5-position by quantifying the inhibition of the basal Eg5 ATPase activity. The results are summarised in Tables 1 to 4 .
We first investigated the influence of the 5-methyl group on the Eg5 inhibitory activity (Table 1) Exchanging the planar 5-phenyl group with a staggered cyclohexyl substituent (4) led to a 10-fold drop in activity (7.5 ± 2.3 μM), indicating that the planar phenyl ring establishes better hydrophobic interactions in this part of the inhibitor-binding pocket. 
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We then investigated the inhibitor effects of a range of analogues in which the 5phenyl group was substituted with a variety of alkyl groups of varying length (cmpds 5 to 16). Although we expected at least some inhibitory activity because placing a hydrophobic substituent into an essentially hydrophobic pocket should lead to at least some favourable interactions, to our surprise none of the tested analogues fully inhibited Eg5 activity. However, there is a clear trend between the length of the alkyl chain and the extend of inhibition with the most extended alkyl chains in this position (cmpds 15 and 16) indicating partial inhibition of Eg5 activity of up to 60% (Table 1) .
From the crystal structure of Eg5-(R)-K858 complex, an interesting edge-to-face (Tshaped) aromatic stacking interaction was observed between the phenyl ring (edge) of Trp211 and phenyl group (face) of thiadiazole scaffold, which is essential for the effective binding and subsequent inhibition of Eg5 besides having good hydrophobic interactions with key residues Arg119 and Pro137. This specific edge-to-face stacking interaction was not exhibited by the analogues containing hydrophobic alkyl chains. Although being hydrophobic in nature, they can only establish weaker long distance hydrophobic interactions disfavored by a higher conformational freedom, which are, however, not sufficient for effective inhibition. In our previous published work, we had observed similar crucial edge-to-face contacts involving phenyl groups between STLC (Eg5 inhibitor) and Eg5 [32] . These data clearly identify the phenyl group as a crucial substituent of the thiadiazole scaffold for effectively inhibiting Eg5.
We then examined rK858 analogues, in which the methyl and phenyl substituents at the 5-position are combined into alicyclic substituents of increasing ring sizes and additional substituents at the cyclohexyl ring system ( Table 2 ). Neither 5-, 6-, substituted 6-, 7-or 8-membered ring systems displayed any inhibitory activity against Eg5 thus suggesting that a certain degree of conformational freedom is requested in this position as they can be considered as cyclic analogues of derivatives 7-16. In summary synthesising analogues, which combine the two substituents at the asymmetric carbon atom into non-aromatic, cyclic substituents (17-25) did also not lead to more potent K858 analogues. 
A group of analogues incorporating various heterocyclic rings in the 5-position instead of the phenyl group resulted in a variety of active analogues (cmpds 26 to 37, Table 3 ). Whereas cmpd 26, in which the phenyl group is substituted by a furan ring system has a slightly lower IC 50 value of 4.3 ± 0.9 μM, cmpd 28 with an unsaturated thiophen-2-yl substituent (bioisosteric replacement) displayed an IC 50 value of 1.7 ± 0.1 μM. When the thiophene system is coordinated to the thiadiazole ring system through its 3-position, the IC 50 is still 2. diazine scaffold is a weak inhibitor of Eg5 (IC 50 value of 46.9 ± 6.9 μM). 
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Me Pyrazin-2-yl 46.9 ± 6.9 (70) Table 4 contains K858 analogues with ortho-, meta-and para-substitutions at the structural phenyl ring system (38) (39) (40) (41) (42) as well as fused ring substituents (43) (44) (45) (46) (47) . It is interesting to note that all three thiadiazole-based Eg5 inhibitors (Figure 1 ) retain the 5-phenyl group as a substituent and we can safely assume that the clinically relevant compounds such as (S)-ARRY-520 and (R)-Litronesib have certainly gone through extensive chemical optimisation of this substituent (Figure 1 & 3D) , although a SAR study has not been made available for any of these clinically important drugs.
This phenyl group seems to fit snuggly into this pocket and represent an ideal substituent with optimal binding features in this predominantly hydrophobic part of the pocket ( Figure 4C ). To gain more insights about potential structural relationships we compared all available Eg5 inhibitor scaffolds for which structural information is available in the PDB with the binding mode of K858. Interestingly, two types of scaffolds, dihydropyrrole and dihydropyrazole containing Eg5 inhibitors, which are structurally related to the thiadiazole scaffold (Figure 1 , lower panel) can be fully (thiadiazole core, magenta) and MK-0731 (dihydropyrrole core, blue, PDB ID: 3CJO, [33] ). B) Stereoplot of the overlay between (R)-K858 (magenta) and a dihydropyrazole containing scaffold (yellow, PDB ID: 2G1Q, [34] ). All three core structures possess the same substitution pattern and the core as well as the phenyl groups are located in the same part of the inhibitor -binding pocket.
Conclusions
In this study we determined the crystal structure of an Eg5-inhibitor complex containing the 1,3,4-thiadiazole core scaffold, which is present in clinically relevant
Eg5 targeting inhibitors such as (S)-ARRY-520 and (R)-Litronesib. We were also able to determine the IC 50 values of 46 K858 analogues by measuring the inhibition of the basal Eg5 ATPase activity and based on the structural insights gained from the complex we could use this structure for rationalising our SAR study. This will serve as a basis for future structure-based drug design of this very important chemical scaffold.
Materials and methods

Chemistry
All chemicals and reagents (AR grade) were purchased from Sigma-Aldrich and 
Synthesis of racemic K858
Racemic K858 was synthesised as previously described [27, 28] .
(E)-2-(1-phenylethylidene)hydrazine-1-carbothioamide (c)
To a solution of acetophenone a ( The syntheses and characterisation of the other 46 rK858 analogues (2-46) have recently been described in detail [26] .
Enantioselective HPLC.
Enantioselective HPLC analyses were performed by using stainless-steel Chiralpak 
Subcloning, expression and purification of human Eg5
The human Eg5 1-368 motor domain was expressed and purified as previously described [32] .
Steady-state ATPase activity assays
Steady-state basal and MT-stimulated Eg5 ATPase activities were measured using the pyruvate kinase (PK)-lactate dehydrogenase (LDH) coupled assay as described [35] . The quantities of Eg5 used in the basal and MT-stimulated conditions were 150 nM and 10 nM, respectively. The Mg 2+ ATP concentration was fixed at 1 mM and the 
Isothermal titration calorimetry (ITC)
Interactions between Eg5 and K858 were studied by ITC using a MicroCal PEAQ-ITC (Malvern) as previously described, but with some modifications [37, 38] to 10% compared to the amount originally present in the reservoir solution. The time for dehydration varied between three days to a week. Eventually, plate-like crystals appeared and these crystals diffracted to a significantly higher resolution compared to the original needle-like crystals.
Crystals obtained in space group P6 5 
Data collection, structure determination, refinement and model quality
Diffraction data for the two distinct crystal forms were collected at the European Synchrotron Radiation Facility (ESRF), beamline ID30A-1. Data were processed using either XDS [39] or iMosflm [40] and scaled to resolutions as mentioned in Table   6 [41]. The structures of the Eg5-rK858 complex were solved in two space groups by molecular replacement (PHASER MR in CCP4 suite) using a previously published Eg5 structure (PDB ID: 1X88, [42] ) as a search model. All structures were initially refined with REFMAC5 [43] . Electron density and difference density maps, all σAweighted, were inspected, and the models were improved using Coot [44] . Further refinement of the structures was performed using PHENIX [45] . The calculation of R free used 5% of data. Crystallographic and refinement statistics are given in Table 6 .
Both space groups contain one Eg5-rK858 complex per AU. The complexes cover residues Lys17 to Glu364 and Asn18 to Glu367 in space groups C222 1 and P6 5 22, respectively. In the former space group, loops containing residues 56-60, 176-179, 249-243 and 272-286 are missing in the structure, whereas in the latter space group the regions 34-35 and 272-287 are absent. 
